Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Doxil: Phase III data; MAA under review; marketed

In a 474-patient Phase III trial, a 1-hour infusion of Doxil gave a

Read the full 137 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE